Front Cover: Conditional PROTAC: Recent Strategies for Modulating Targeted Protein Degradation (ChemMedChem 22/2024)

IF 3.6 4区医学 Q2 CHEMISTRY, MEDICINAL

ChemMedChem Pub Date : 2024-11-21 DOI:10.1002/cmdc.202482201

Dr. Junhyeong Yim, Junyoung Park, Gabin Kim, Hyung Ho Lee, Jin Soo Chung, Dr. Ala Jo, Prof. Minseob Koh, Prof. Jongmin Park

引用次数: 0

Abstract

To overcome the limitations of conventional PROTACs, conditional PROTACs have been recently developed. Activated conditional PROTACs (red glow colored) can generate the proximity between target proteins (purple colored) and E3 ligases (blue colored) and trigger the targeted protein degradation in spatio-, temporal-, or spatiotemporal way to enhance the efficacy, specificity, and delivery of PROTACs. More details can be found in article 10.1002/cmdc.202400326 by Ala Jo, Minseob Koh, Jongmin Park, and co-workers.

Abstract Image

查看原文本刊更多论文

封面：条件性 PROTAC：调控靶向蛋白质降解的最新策略（ChemMedChem 22/2024）

为了克服传统 PROTACs 的局限性，最近开发出了条件 PROTACs。激活的条件PROTACs（红光色）能使靶蛋白（紫色）和E3连接酶（蓝色）之间产生接近性，并以时空或时空方式触发靶蛋白降解，从而提高PROTACs的效力、特异性和递送。更多详情请见 Ala Jo、Minseob Koh、Jongmin Park 及合作者撰写的文章 10.1002/cmdc.202400326。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ChemMedChem 医学-药学

CiteScore

6.70

自引率

2.90%

发文量

280

审稿时长

1 months

期刊介绍： Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies. ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs. Contents ChemMedChem publishes an attractive mixture of: Full Papers and Communications Reviews and Minireviews Patent Reviews Highlights and Concepts Book and Multimedia Reviews.